This Article Full Text Full Text (PDF) Supplementary Data, Risinger, et al. Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Risinger, J. I. Articles by Barrett, J. C. Search for Related Content PubMed PubMed Citation Articles by Risinger, J. I. Articles by Barrett, J. C.

Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression

Authors' Affiliations: ¹ Center for Cancer Research, National Cancer Institute; ² National Institute of Allergy and Infectious Diseases, Bethesda Maryland; ³ Walter Reed Army Medical Center, Washington, District of Columbia; and ⁴ Department of Obstetrics and Gynecology/Division of Gynecologic Oncology and the Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina

Requests for reprints: John Ian Risinger, Memorial Health University Medical Center, Curtis and Elizabeth Anderson Cancer Institute, 4700 Waters Avenue, Savannah, GA 31404. Phone: 912-350-0960; Fax: 912-350-8199; E-mail: risinJo1{at}memorialhealth.com.

Purpose: Cancer/testis (CT) genes predominantly expressed in the testis (germ cells) and generally not in other normal tissues are aberrantly expressed in human cancers. This highly restricted expression provides a unique opportunity to use these CT genes for diagnostics, immunotherapeutic, or other targeted therapies. The purpose of this study was to identify those CT genes with the greatest incidence of expression in uterine cancers.

Experimental Design: We queried the expression of known and putative CT gene transcripts (representing 79 gene loci) using whole genome gene expression arrays. Specifically, the global gene expressions of uterine cancers (n = 122) and normal uteri (n = 10) were determined using expression data from the Affymetrix HG-U133A and HG-U133B chips. Additionally, we also examined the brother of the regulator of imprinted sites (BORIS) transcript by reverse transcription-PCR and quantitative PCR because its transcript was not represented on the array.

Results: Global microarray analysis detected many CT genes expressed in various uterine cancers; however, no individual CT gene was expressed in more than 25% of all cancers. The expression of the two most commonly expressed CT genes on the arrays, MAGEA9 (24 of 122 cancers and 0 of 10 normal tissues) and Down syndrome critical region 8 (DSCR8)/MMA1 (16 if 122 cancers and 0 of 10 normal tissues), was confirmed by reverse transcription-PCR methods, validating the array screening approach. In contrast to the relatively low incidence of expression of the other CT genes, BORIS expression was detected in 73 of 95 (77%) endometrial cancers and 24 of 31 (77%) uterine mixed mesodermal tumors.

Conclusions: These data provide the first extensive survey of multiple CT genes in uterine cancers. Importantly, we detected a high frequency of BORIS expression in uterine cancers, suggesting its potential as an immunologic or diagnostic target for these cancers. Given the high incidence of BORIS expression and its possible regulatory role, an examination of BORIS function in the etiology of these cancers is warranted.

This article has been cited by other articles:

				O. Aprelikova, S. Pandolfi, S. Tackett, M. Ferreira, K. Salnikow, Y. Ward, J. I. Risinger, J. C. Barrett, and J. Niederhuber Melanoma Antigen-11 Inhibits the Hypoxia-Inducible Factor Prolyl Hydroxylase 2 and Activates Hypoxic Response Cancer Res., January 15, 2009; 69(2): 616 - 624. [Abstract] [Full Text] [PDF]

				S. Renaud, E. M. Pugacheva, M. D. Delgado, R. Braunschweig, Z. Abdullaev, D. Loukinov, J. Benhattar, and V. Lobanenkov Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors Nucleic Acids Res., December 18, 2007; 35(21): 7372 - 7388. [Abstract] [Full Text] [PDF]